Cancer Chemotherapy and Pharmacology

, Volume 66, Issue 2, pp 265–267 | Cite as

Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report

  • Daniel P. Greene
  • James Stuart Ferriss
  • Amir A. Jazaeri
Original Article



Platinum-based therapy is the cornerstone of ovarian cancer treatment. Development of platinum hypersensitivity can limit therapeutic options. In this brief report, we present case of successful cisplatin administration following two unsuccessful carboplatin desensitization attempts, and without the need for pre-treatment steroids.


Retrospective chart review was performed.


One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin-based regimen, developed a platinum hypersensitivity. Two attempts at carboplatin desensitization were unsuccessful. Cisplatin was substituted and the patient achieved a complete response to therapy without further hypersensitivity.


Platinum-based therapies are vital to the treatment of primary peritoneal and ovarian carcinoma. Protocols that successfully incorporate platinum agents, despite a platinum hypersensitivity, are clinically relevant.


Platinum hypersensitivity Peritoneal carcinoma Platinum desensitization failure Cisplatin 


  1. 1.
    Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin–DNA adducts. Chem Rev 99(9):2467–2498CrossRefPubMedGoogle Scholar
  2. 2.
    Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA et al (2006) Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol 195(2):568–574 (discussion 574–576)CrossRefPubMedGoogle Scholar
  3. 3.
    Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43CrossRefPubMedGoogle Scholar
  4. 4.
    Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200CrossRefPubMedGoogle Scholar
  5. 5.
    Sliesoraitis S, Chikhale PJ (2005) Carboplatin hypersensitivity. Int. J. Gynecol. Cancer 15(1):13–18CrossRefPubMedGoogle Scholar
  6. 6.
    Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ et al (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9(7):1138–1150PubMedGoogle Scholar
  7. 7.
    Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR (2002) Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 84(3):378–382CrossRefPubMedGoogle Scholar
  8. 8.
    Rose PG, Fusco N, Smrekar M, Mossbruger K, Rodriguez M (2003) Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 89(3):429–433CrossRefPubMedGoogle Scholar
  9. 9.
    Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK (2001) Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 82(3):550–558CrossRefPubMedGoogle Scholar
  10. 10.
    McGuire WP, Ozols RF (1998) Chemotherapy of advanced ovarian cancer. Semin Oncol 25(3):340–348PubMedGoogle Scholar
  11. 11.
    Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, Jazaeri AA (2007) Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol 197(2):199e.1–199e.14 (discussion 199.e4–e5)CrossRefGoogle Scholar
  12. 12.
    Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J (2004) Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 64(1):356–362CrossRefPubMedGoogle Scholar
  13. 13.
    Zweizig S, Roman LD, Muderspach LI (1994) Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 53(1):121–122CrossRefPubMedGoogle Scholar
  14. 14.
    Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J (2003) Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 21(24):4611–4614CrossRefPubMedGoogle Scholar
  15. 15.
    Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV et al (2009) Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 123(6):1262–1267CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Daniel P. Greene
    • 1
  • James Stuart Ferriss
    • 2
  • Amir A. Jazaeri
    • 2
  1. 1.University of Virginia School of MedicineCharlottesvilleVAUSA
  2. 2.Thornton Gynecologic Oncology Service, Department of Obstetrics and GynecologyUniversity of Virginia Health SystemCharlottesvilleUSA

Personalised recommendations